English
fadrozole
Sign in to saveAlso known as Afema®, CGS 16949 A, CGS-16949A, FAD 286, FAD-286
Fadrozole (), sold under the brand name Afema (by Novartis), is a selective, nonsteroidal aromatase inhibitor which is or has been used in Japan for the treatment of breast cancer.
Research
557 papers- Fadrozole and letrozole in advanced breast cancer: clinical and biochemical effects.Breast cancer research and treatment · 1998
- Fadrozole-mediated sex reversal in the embryonic chicken gonad involves a PAX2 positive undifferentiated supporting cell state.Frontiers in cell and developmental biology · 2022
- Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?Journal of hypertension · 2006
- Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: discordant enantioselectivity versus reduction of plasma aldosterone.Endocrinology · 2008
- The effect of aromatase inhibitor, fadrozole, on sGnRHa stimulated LH secretion in goldfish (Carassius auratus) and common carp (Cyprinus carpio).Reproductive biology · 2006
via PubMed
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Fadrozole (), sold under the brand name Afema (by Novartis), is a selective, nonsteroidal aromatase inhibitor which is or has been used in Japan for the treatment of breast cancer.
==References==
Excerpted from Wikipedia’s “fadrozole” article, available under the CC BY-SA 4.0 licence.